Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Telix Pharmaceuticals ( (AU:TLX) ).
Citigroup Global Markets Australia and related Citi group entities have notified Telix Pharmaceuticals that they have ceased to be a substantial holder in the company as of 8 April 2026. The change reflects net reductions in their relevant interest in Telix’s ordinary fully paid shares, primarily through adjustments in positions held under securities lending agreements across several Citi affiliates.
The filing details decreases in holdings by Citibank N.A. Sydney Branch and Citigroup Global Markets Australia, partially offset by small increases at other Citi entities including Citigroup Global Markets Inc and Citigroup Global Markets Limited. While the overall stake has fallen below the substantial holder threshold, the shifts appear driven by routine securities lending and trading activity rather than a disclosed strategic move, signalling a technical change in Telix’s share register that investors may monitor for liquidity and ownership dynamics.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$24.30 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
More about Telix Pharmaceuticals
Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercialising radiopharmaceuticals for the diagnosis and treatment of cancer and other serious diseases. The company targets global oncology markets with a portfolio of imaging and therapeutic products designed to improve precision medicine and patient outcomes.
Average Trading Volume: 3,169,922
Technical Sentiment Signal: Hold
Current Market Cap: A$4.63B
For an in-depth examination of TLX stock, go to TipRanks’ Overview page.